Capricor Therapeutics enters the July 8 week at $22.22 — down another 7.7% over the past five sessions — with short interest back above 31% of the free float and the August 6 earnings date now less than a month away.
The short build has resumed. After Thursday's session showed a sharp single-day drop in shares short — the notable relief flagged in the July 4 note — that cover has reversed. Bears now hold 31.0% of the free float, or approximately 14.2 million shares, up 7.2% on the week and 24% over the past month. The month-long accumulation is the dominant trend, and the latest weekly move confirms that the mid-week relief was a pause rather than a turn. The ORTEX short score is 77.3, essentially flat from the 76.7 level of a few days ago, and still ranking in just the 6th percentile of the ORTEX universe — meaning 94% of stocks in the database carry a less bearish short-positioning profile.
The borrow market remains the stubborn contradiction in this setup. Despite a short position that has grown by nearly a quarter in a month, cost to borrow has actually eased — falling 9% on the week to just 0.54%. Availability is loose at 173%, meaning roughly 29 million shares are available to lend against the ~14 million already out on loan. The lending pool has actually expanded over the past week: availability was 127% on June 30 and is now at 173%, a 36% weekly increase. That pattern — rising short interest alongside falling borrow costs and expanding availability — indicates new supply of lendable shares is entering the market as fast as bears are borrowing them. Squeeze mechanics are not the story here; the bears are building a large, cheap, well-funded position. Options lean modestly more defensive than usual: the put/call ratio is 0.43, running about 1.6 standard deviations above its 20-day average of 0.38. That is elevated, but nowhere near alarming — the 52-week high on that ratio is 3.16, so the current reading sits in the low end of the historical range.
The peer universe is not offering CAPR much cover. Close correlated names GERN and DYN gained 14.6% and 12.1% respectively on the week, while VKTX added 6.6%. CAPR's 7.7% weekly loss stands in sharp contrast to that group — it is the clear laggard among its closest correlated biotech peers, which points to stock-specific pressure rather than a broad sector move. The Piotroski F-score of 2, deeply negative EPS yield, and negative EV/EBITDA all reflect the pre-profitability stage of the business. That is expected for a clinical-stage name, but it narrows the valuation floor argument considerably.
On the institutional side, the most recent quarterly data shows active managers adding exposure: Suvretta Capital added nearly 2.9 million shares to Q1, Tang Capital added 1.7 million, and State Street added 1.4 million, each building in the March quarter. BlackRock added a further 571,000 shares as recently as June 30. Those are material accumulation moves. But they sit alongside the insider picture, which has not changed: the CFO and General Counsel sold on three consecutive trading sessions in late June at prices of $30.00–$30.38, well above the current $22.22. The 90-day net insider flow remains solidly negative at roughly $8.4 million in aggregate sales and no purchases. Institutions are buying; management is selling.
The next inflection point is the August 6 earnings print. The May 12 Q1 report produced a 4.9% one-day loss and a 15.6% five-day decline, so the stock's history with earnings is asymmetric to the downside. With short interest still building, insiders having sold at $30 while the stock now trades at $22, and biotech peers outperforming on the week, the distance between institutional conviction and market pricing is the key tension to track into that August date.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
